JAZZ PHARMACEUTICALS, INC.

Lobbying for JAZZ PHARMACEUTICALS, INC.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 16, 2026

Expenses

$490,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 5

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 946
ORPHAN Cures Act

Lobbying activity 1

Pharmacy

FDA regulation of CBD FDA Rare Disease PPRV program/reauthorization Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Most Favored Nation drug pricing Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act HR 946: Orphan Cures Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.